A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
19 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Healthy adult male and/or females, 19 to 60 years of age, inclusive.
Medically healthy with no clinically significant screening results as deemed by the PI.
History of presence of clinically significant medical condition or disease in the opinion of the PI.
Alcoholism or drug abuse.
Female subjects who are pregnant or lactating.
Known history or evidence of active hepatitis A, B, or C or HIV.
Clinically significant cardiovascular disease.
Participation in another clinical trial within 28 days prior to the first dose of GMI-1271 or filgrastim, whichever occurs first.